Evaluating the Safety of HCAR19 (Now Actalycabtagene Autoleucel- Actaly-CelT), a Novel Humanized CD19-Directed Chimeric Antigen Receptor T-Cells in Pediatric, Adolescents, and Young Adults with Relapsed/ Refractory B- Acute Lymphoblastic Leukemia (ESHA) - Report of Phase-1B

被引:2
|
作者
Narula, Gaurav [1 ]
Keerthivasagam, Swaminathan [2 ]
Jain, Hasmukh [1 ]
Dhamne, Chetan [2 ]
Tembhare, Prashant [3 ]
Subramanian, Papagudi Ganesan [3 ]
Patkar, Nikhil [3 ]
Poojary, Minal [4 ]
Nisar, Albeena [5 ]
Pandit, Deepali [6 ]
Pandit, Khushali [7 ]
Karulkar, Atharva [8 ]
Jaiswal, Ankesh Kumar [8 ]
Khan, Aalia [8 ]
Shah, Shreshtha [8 ,9 ]
Firfiray, Afrin [8 ]
Pendhari, Juber [8 ]
Asija, Sweety [8 ]
Chowdury, Ambalika [8 ]
Banik, Ankit [8 ]
Moulik, Nirmalya Roy [2 ]
Srinivasan, Shyam [10 ]
Bhosle, Shilpushp [11 ]
Hiregoudar, Sumathi [3 ]
Ojha, Shashank [3 ]
Nayak, Lingaraj [3 ,12 ]
Thorat, Jayshree [13 ]
Bagal, Bhausaheb [3 ,12 ]
Sengar, Manju [1 ]
Jindal, Nishant [3 ,12 ]
Chichra, Akanksha [12 ]
Mirgh, Sumeet [3 ,12 ]
Gokarn, Anant [3 ,12 ]
Punatar, Sachin [3 ,12 ]
Rajadhyaksha, Sunil [14 ]
Khattry, Navin [3 ,12 ]
Banavali, Shripad [15 ]
Highfill, Steven [16 ]
Shah, Nirali N. [17 ]
Purwar, Rahul [18 ]
机构
[1] Homi Bhabha Natl Inst, Dept Med Oncol, Tata Mem Ctr, Mumbai, Maharashtra, India
[2] Homi Bhabha Natl Inst, Dept Pediat Oncol, Tata Mem Ctr, Mumbai, Maharashtra, India
[3] Homi Bhabha Natl Inst, Dept Hematopathol, Tata Mem Ctr, Adv Ctr Treatment Res & Educ Canc ACTREC, Navi Mumbai, India
[4] Homi Bhabha Natl Inst, Dept Transfus Med, Tata Mem Ctr, Navi Mumbai, India
[5] ACTREC, CAR T & Cell Therapy Ctr, Tata Mem Ctr, Sci Off D, Mumbai, Maharashtra, India
[6] Tata Mem Hosp, CAR T & Cell Therapy Ctr, ACTREC, Kharghar, India
[7] Tata Mem Hosp, CAR T & Cell Therapy Ctr, ACTREC, Mumbai, Maharashtra, India
[8] Indian Inst Technol, Dept Biosci & Bioengn, Mumbai, Maharashtra, India
[9] ImmunoACT, Immunoadopt Cell Therapy Private Ltd, Mumbai, Maharashtra, India
[10] Homi Bhabha Natl Inst, Dept Pediat Oncol, Tata Mem Ctr, Mumbai, Maharashtra, India
[11] Homi Bhabha Natl Inst, Dept Crit Care & Anaesthesiol, Tata Mem Ctr, Mumbai, Maharashtra, India
[12] Homi Bhabha Natl Inst, Dept Med Oncol, BMT Unit,Tata Mem Ctr, Adv Ctr Treatment Res & Educ Canc ACTREC, Navi Mumbai, India
[13] Homi Bhabha Natl Inst, Dept Med Oncol, Tata Mem Ctr, Mumbai, Maharashtra, India
[14] Homi Bhabha Natl Inst, Dept Transfus Med, Tata Mem Ctr, Mumbai, Maharashtra, India
[15] Tata Mem Hosp, Dept Med Oncol, Homi Bhabha Natl Inst, Mumbai, Maharashtra, India
[16] Natl Inst Hlth, Ctr Cellular Engn, Bethesda, MD USA
[17] Natl Inst Hlth, Pediat Oncol Branch, Bethesda, MD USA
[18] Indian Inst Technol B, Dept Biosci & Bioengn, Mumbai, Maharashtra, India
关键词
D O I
10.1182/blood-2023-180867
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页数:6
相关论文
共 28 条
  • [11] Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
    Maude, Shannon L.
    Hucks, George E.
    Callahan, Colleen
    Baniewicz, Diane
    Fasano, Christina
    Barker, Christine
    Rheingold, Susan R.
    Aplenc, Richard
    Dinofia, Amanda M.
    Li, Amanda
    Teachey, David T.
    Barrett, David M.
    Brogdon, Jennifer
    Young, Regina M.
    Scholler, John
    Marcucci, Katherine T.
    Levine, Bruce L.
    Frey, Noelle
    Porter, David L.
    Lacey, Simon F.
    Melenhorst, J. Joseph
    June, Carl H.
    Grupp, Stephan A.
    BLOOD, 2017, 130
  • [12] CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial
    Cordoba, Shaun
    Onuoha, Shimobi
    Thomas, Simon
    Pignataro, Daniela Soriano
    Hough, Rachael
    Ghorashian, Sara
    Vora, Ajay
    Bonney, Denise
    Veys, Paul
    Rao, Kanchan
    Lucchini, Giovanna
    Chiesa, Robert
    Chu, Jan
    Clark, Liz
    Fung, Mei Mei
    Smith, Koval
    Peticone, Carlotta
    Al-Hajj, Muhammad
    Baldan, Vania
    Ferrari, Mathieu
    Srivastava, Saket
    Jha, Ram
    Vargas, Frederick Arce
    Duffy, Kevin
    Day, William
    Virgo, Paul
    Wheeler, Lucy
    Hancock, Jeremy
    Farzaneh, Farzin
    Domning, Sabine
    Zhang, Yiyun
    Khokhar, Nushmia Z.
    Peddareddigari, Vijay G. R.
    Wynn, Robert
    Pule, Martin
    Amrolia, Persis J.
    NATURE MEDICINE, 2021, 27 (10) : 1797 - +
  • [13] CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial
    Shaun Cordoba
    Shimobi Onuoha
    Simon Thomas
    Daniela Soriano Pignataro
    Rachael Hough
    Sara Ghorashian
    Ajay Vora
    Denise Bonney
    Paul Veys
    Kanchan Rao
    Giovanna Lucchini
    Robert Chiesa
    Jan Chu
    Liz Clark
    Mei Mei Fung
    Koval Smith
    Carlotta Peticone
    Muhammad Al-Hajj
    Vania Baldan
    Mathieu Ferrari
    Saket Srivastava
    Ram Jha
    Frederick Arce Vargas
    Kevin Duffy
    William Day
    Paul Virgo
    Lucy Wheeler
    Jeremy Hancock
    Farzin Farzaneh
    Sabine Domning
    Yiyun Zhang
    Nushmia Z. Khokhar
    Vijay G. R. Peddareddigari
    Robert Wynn
    Martin Pule
    Persis J. Amrolia
    Nature Medicine, 2021, 27 : 1797 - 1805
  • [14] 3rd-Generation CD19-directed Chimeric Antigen Receptor T-Cells (CARTs) for Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) - Status report of the Ongoing Academic Phase 1/2 Trial (HD-CAR-1)
    Derigs, P.
    Kunz, A.
    Dreger, P.
    Schmitt, A.
    Schubert, M. -L
    Brueggemann, M.
    Bernhard, H.
    Kobbe, G.
    Lindemann, A.
    Rummel, M.
    Wang, L.
    Michels, B.
    Waldho, P.
    Korell, F.
    Laier, S.
    Ho, A. D.
    Mueller-Tidow, C.
    Schmitt, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 74 - 74
  • [15] 3rd-generation CD19-directed chimeric antigen receptor t-cells (carts) for relapsed/refractory chronic lymphocytic leukemia (cll) - results from an academic phase 1/2 trial (hd-car-1)
    Derigs, P.
    Kunz, A.
    Dreger, P.
    Schmitt, A.
    Schubert, M. -L.
    Brueggemann, M.
    Bernhard, H.
    Kobbe, G.
    Lindemann, A.
    Rummel, M.
    Wang, L.
    Michels, B.
    Waldhoff, P.
    Korell, F.
    Pavel, P.
    Ho, A. D.
    Muller-Tidow, C.
    Schmitt, M.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 129 - 130
  • [16] 3RD-GENERATION CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELLS (CARTS) FOR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - UPDATE ON THE ONGOING ACADEMIC PHASE 1/2 TRIAL (HD-CAR-1)
    Derigs, P.
    Kunz, A.
    Dreger, P.
    Schmitt, A.
    Schubert, M. -L.
    Brueggemann, M.
    Bernhard, H.
    Kobbe, G.
    Lindemann, A.
    Rummel, M.
    Wang, L.
    Michels, B.
    Waldhoff, P.
    Korell, F.
    Laier, S.
    Ho, A. D.
    Mueller-Tidow, C.
    Schmitt, M.
    HUMAN GENE THERAPY, 2023, 34 (21-22) : A7 - A8
  • [17] ZUMA-4 Phase 1: KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Children and Adolescents with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
    Wayne, A. S.
    Huynh, V.
    Hijiya, N.
    Rouce, R.
    Brown, P. A.
    Krueger, J.
    Rytting, M.
    Kitko, C. L.
    Dela Ziga, E.
    Hermiston, M.
    Richards, M. K.
    Baruchel, A.
    Mardiros, A.
    Shen, T.
    Goyal, L.
    Vezan, R.
    Jain, R.
    Lee, D. W.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S7 - S7
  • [18] HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation
    Xin Jin
    Yaqing Cao
    Luqiao Wang
    Rui Sun
    Lin Cheng
    Xiaoyuan He
    Xia Xiao
    Yili Jiang
    Qing Li
    Huan Zhang
    Wenyi Lu
    Cuicui Lyu
    Yanyu Jiang
    Juanxia Meng
    Mingfeng Zhao
    Leukemia, 2020, 34 : 909 - 913
  • [19] HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation
    Jin, Xin
    Cao, Yaqing
    Wang, Luqiao
    Sun, Rui
    Cheng, Lin
    He, Xiaoyuan
    Xiao, Xia
    Jiang, Yili
    Li, Qing
    Zhang, Huan
    Lu, Wenyi
    Lyu, Cuicui
    Jiang, Yanyu
    Meng, Juanxia
    Zhao, Mingfeng
    LEUKEMIA, 2020, 34 (03) : 909 - 913
  • [20] Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma
    Gauthier, Jordan
    Hirayama, Alexandre V.
    Hay, Kevin A.
    Sheih, Alyssa
    Pender, Barbara S.
    Hawkins, Reed M.
    Vakil, Aesha
    Tinh-Doan Phi
    Steinmetz, Rachel N.
    Chapuis, Aude G.
    Till, Brian G.
    Kiem, Hans-Peter
    Shadman, Mazyar
    Cassaday, Ryan D.
    Acharya, Utkarsh H.
    Riddell, Stanley R.
    Maloney, David G.
    Turtle, Cameron J.
    BLOOD, 2018, 132